Chronic Kidney Disease (CKD) Staging & Diabetic/Hypertensive Nephropathy
Key Takeaways
- CKD is defined as kidney damage or eGFR < 60 mL/min/1.73m² for >= 3 months; staging is based on KDIGO eGFR categories (G1-G5) and Albuminuria categories (A1-A3).
- ACE inhibitors or ARBs are first-line therapy for patients with hypertension, CKD, and albuminuria (UACR >= 30 mg/g); a transient creatinine rise up to 30% after initiation is acceptable.
- SGLT2 inhibitors (Dapagliflozin, Empagliflozin) slow CKD progression and lower ESRD risk in both diabetic and non-diabetic kidney disease with eGFR >= 20 mL/min/1.73m².
- Systemic complications of advanced CKD include normocytic anemia (treated with iron and ESAs for target Hb 10-11.5 g/dL) and CKD-MBD (hyperphosphatemia, hypocalcemia, secondary hyperparathyroidism).
- Nephrotoxic drugs—especially NSAIDs, iodinated radiocontrast, and aminoglycosides—must be strictly avoided in patients with compromised GFR.
Chronic Kidney Disease (CKD) Staging & Diabetic/Hypertensive Nephropathy
Chronic Kidney Disease (CKD) is defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines as abnormalities of kidney structure or function present for greater than 3 months, with significant implications for health. The primary etiologies of CKD in developed nations are Diabetic Kidney Disease (DKD) (~40%) and Hypertensive Nephrosclerosis (~25%), followed by chronic glomerulonephritis, polycystic kidney disease, and tubulointerstitial nephritis.
KDIGO CKD Staging Framework
KDIGO staging mandates a dual classification system combining estimated Glomerular Filtration Rate (eGFR, G-stage) and Urine Albumin-to-Creatinine Ratio (UACR, A-stage). Combining G and A categories predicts cardiorenal outcomes, progression to End-Stage Renal Disease (ESRD), and overall mortality.
eGFR Categories (G-Stages)
- Stage G1: Normal or high, eGFR >= 90 mL/min/1.73m² (requires presence of structural damage, proteinuria, or histology abnormalities to diagnose CKD).
- Stage G2: Mildly decreased, eGFR 60–89 mL/min/1.73m² (requires kidney damage evidence).
- Stage G3a: Mildly to moderately decreased, eGFR 45–59 mL/min/1.73m².
- Stage G3b: Moderately to severely decreased, eGFR 30–44 mL/min/1.73m².
- Stage G4: Severely decreased, eGFR 15–29 mL/min/1.73m² (warrants immediate Nephrology referral and vascular access planning).
- Stage G5: Kidney Failure, eGFR < 15 mL/min/1.73m² (ESRD requiring renal replacement therapy/dialysis or renal transplantation).
Albuminuria Categories (A-Stages)
- Stage A1: Normal to mildly increased, UACR < 30 mg/g (< 3 mg/mmol).
- Stage A2: Moderately increased (formerly microalbuminuria), UACR 30–300 mg/g (3–30 mg/mmol).
- Stage A3: Severely increased (formerly macroalbuminuria), UACR > 300 mg/g (> 30 mg/mmol; includes nephrotic range > 2200 mg/g).
| eGFR Category | A1 (UACR < 30 mg/g) | A2 (UACR 30–300 mg/g) | A3 (UACR > 300 mg/g) |
|---|---|---|---|
| G1 (>= 90) | Low Risk (if no kidney damage) | Moderate Risk | High Risk |
| G2 (60–89) | Low Risk (if no kidney damage) | Moderate Risk | High Risk |
| G3a (45–59) | Moderate Risk | High Risk | Very High Risk |
| G3b (30–44) | High Risk | Very High Risk | Very High Risk |
| G4 (15–29) | Very High Risk | Very High Risk | Very High Risk |
| G5 (< 15) | Very High Risk | Very High Risk | Very High Risk |
Pathophysiology of DKD & Hypertensive Nephrosclerosis
Diabetic Kidney Disease (DKD)
Hyperglycemia drives intraglomerular hypertension via afferent arteriolar vasodilation paired with efferent arteriolar vasoconstriction (mediated by angiotensin II). Over years, hyperfiltration leads to mesangial matrix expansion, glomerular basement membrane thickening, podocyte loss, and progressive nodular glomerulosclerosis (Kimmelstiel-Wilson lesions). Clinically, this manifests as microalbuminuria (A2), progressing to overt proteinuria (A3), and eventual GFR decline.
Hypertensive Nephrosclerosis
Chronic arterial hypertension causes hyaline arteriolosclerosis of renal afferent arterioles. Luminal narrowing results in chronic renal ischemia, glomerular collapse, focal segmental glomerulosclerosis, and tubulointerstitial fibrosis.
Evidence-Based Pharmacotherapy to Slow CKD Progression
Management centers on aggressive blood pressure control and targeted renoprotective medications.
1. ACE Inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs)
- Indication: First-line therapy for patients with CKD, hypertension, and albuminuria (UACR >= 30 mg/g), regardless of diabetic status.
- Mechanism: Selectively dilate the efferent arteriole, reducing intraglomerular hydrostatic pressure and urinary protein excretion.
- Monitoring & Dosing Rules:
- Measure serum creatinine and potassium 1 to 2 weeks after initiating or uptitrating an ACEi or ARB.
- The 30% Rule: A transient increase in serum creatinine of up to 30% above baseline is an expected hemodynamic response reflecting reduced intraglomerular pressure. Do NOT discontinue the medication if the creatinine rise is <= 30% and potassium is acceptable.
- Discontinue or reduce dose only if creatinine increases > 30% or if unmanageable hyperkalemia (> 5.5 mEq/L) develops.
- Never combine an ACEi with an ARB due to increased risks of hyperkalemia and acute kidney injury without additive benefit.
2. SGLT2 Inhibitors (Dapagliflozin, Empagliflozin)
- Indication: Recommended by KDIGO guidelines for adults with CKD (eGFR >= 20 mL/min/1.73m² with UACR >= 200 mg/g, or eGFR 20–60 mL/min/1.73m²) both with and without T2DM.
- Mechanism: Restores tubuloglomerular feedback by increasing sodium delivery to the macula densa, promoting afferent arteriolar vasoconstriction and lowering intraglomerular pressure.
- Clinical Benefit: Reduces the risk of eGFR decline, ESRD, cardiovascular death, and heart failure hospitalizations.
3. Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone)
- Indication: Indicated for adults with T2DM associated with CKD (eGFR >= 25 mL/min/1.73m², UACR >= 30 mg/g, and serum potassium <= 4.8 mEq/L).
- Mechanism: Blocks mineralocorticoid receptor overactivation, inhibiting renal inflammation and fibrosis.
- Benefit: Reduces kidney failure risk and cardiovascular events with a significantly lower risk of hyperkalemia compared to traditional steroidal MRAs (Spironolactone).
4. Blood Pressure Control Targets
KDIGO guidelines recommend targeting a Systolic Blood Pressure < 120 mmHg (using standardized office measurement) in patients with CKD, if tolerated, to maximize renal and cardiovascular protection.
Managing Systemic Complications of Advanced CKD
As eGFR declines below 45 mL/min/1.73m² (Stage G3b–G5), loss of endocrine and excretory function causes multisystem complications:
Anemia of CKD
Caused by decreased renal synthesis of erythropoietin (EPO) by peritubular interstitial cells.
- Diagnostic Evaluation: Rule out nutritional deficiencies. Measure serum ferritin and Transferrin Saturation (TSAT).
- Iron Repletion: Prior to initiating Erythropoiesis-Stimulating Agents (ESAs), iron stores must be adequate (Target Ferritin > 100 ng/mL, TSAT > 20%).
- ESA Therapy (Epoetin alfa, Darbepoetin alfa): Indicated when Hemoglobin is < 10 g/dL. Target Hemoglobin is strictly 10.0 to 11.5 g/dL. Black Box Warning: Normalizing hemoglobin (> 13 g/dL) with ESAs markedly increases the risk of stroke, myocardial infarction, venous thromboembolism, and mortality.
CKD-Mineral and Bone Disorder (CKD-MBD)
Impaired phosphate excretion leads to hyperphosphatemia. Concurrently, reduced renal 1-alpha-hydroxylase activity decreases active Vitamin D (Calcitriol) production, causing hypocalcemia. Hypocalcemia and hyperphosphatemia stimulate parathyroid chief cells, leading to Secondary Hyperparathyroidism and renal osteodystrophy.
- Management:
- Dietary phosphate restriction.
- Phosphate Binders: Taken with meals to bind dietary phosphorus. Non-calcium-based binders (Sevelamer carbonate) are preferred over calcium-based binders (Calcium acetate) to prevent vascular calcification.
- Active Vitamin D Analogs: Calcitriol or Paricalcitol to suppress PTH.
Metabolic Acidosis & Hyperkalemia
- Metabolic Acidosis: Impaired hydrogen ion excretion; treat with oral Sodium Bicarbonate when serum bicarbonate is < 22 mEq/L to slow CKD progression.
- Hyperkalemia: Manage chronic hyperkalemia using oral potassium binders (Patiromer or Sodium Zirconium Cyclosilicate) to allow continued renoprotective ACEi/ARB therapy.
Nephrotoxic Drug Avoidance
Clinicians must vigilantly screen and avoid nephrotoxic agents in CKD patients:
- NSAIDs (Ibuprofen, Naproxen, Celecoxib): Inhibit renal prostaglandin synthesis, causing afferent arteriolar vasoconstriction and precipitating acute-on-chronic renal failure.
- Iodinated Radiocontrast: Risk of Contrast-Induced Nephropathy (CIN); hydrate with IV 0.9% normal saline prior to procedure if contrast is unavoidable.
- Aminoglycosides (Gentamicin, Tobramycin): Direct tubular toxicity.
- Dose Adjustments: Adjust doses for Gabapentin, Allopurinol, H2RAs, and DOACs (Apixaban is preferred in advanced CKD/dialysis).
A 58-year-old female with long-standing T2DM and hypertension presents for routine laboratory evaluation. Her labs reveal an eGFR of 34 mL/min/1.73m² and a Urine Albumin-to-Creatinine Ratio (UACR) of 420 mg/g. According to KDIGO guidelines, how is her Chronic Kidney Disease classified?
A 64-year-old male with Stage G3a CKD and hypertension is started on Lisinopril 10 mg daily. Two weeks later, laboratory testing shows his serum creatinine has increased from a baseline of 1.6 mg/dL to 1.9 mg/dL (a 18.75% increase), and his serum potassium is 4.6 mEq/L. What is the most appropriate next step in management?
A 68-year-old patient with Stage G4 CKD (eGFR 22 mL/min/1.73m²) presents with fatigue. Serum lab testing shows Hemoglobin 8.8 g/dL, Ferritin 45 ng/mL, and Transferrin Saturation (TSAT) 14%. What is the most appropriate first step in addressing this patient's anemia?
Which of the following therapeutic mechanisms explains why SGLT2 inhibitors provide renoprotection in patients with Chronic Kidney Disease?